Recursion Pharmaceuticals

“Highly complementary pipeline with approximately 10 clinical readouts expected over the next 18 months (Recursion alone expects 7 clinical trial readouts in that period).”

Several guided readouts did arrive (REC-994 in CCM in September 2024, REC-2282 in NF2 in Q4 2024, REC-4881 FAP data in May and December 2025), but the combined company fell short of ~10: in May 2025 Recursion terminated REC-994, REC-2282 and REC-3964 and cut other programs, the REC-4881 LILAC cancer trial was deprioritised and later terminated without a readout, and the REC-3964 C. difficile readout never occurred.

“REC-4881 Familial Adenomatous Polyposis — preliminary Phase 2 data readout in the first half of 2025; REC-4881 Advanced AXIN1/APC-Mutant Cancers — preliminary Phase 2 data readout in the first half of 2025.”

The FAP readout landed on time: preliminary Phase 1b/2 TUPELO data (median 43% polyp-burden reduction at week 13) were presented at DDW on 4 May 2025. The AXIN1/APC-mutant cancer readout never happened — the LILAC trial was deprioritised after the Exscientia merger and was later listed as terminated by sponsor decision.

“REC-3964 Clostridioides difficile Infection — Phase 2 study initiation in the fourth quarter of 2024 and preliminary data readout by the end of 2025.”

The Phase 2 ALDER trial did start on schedule — first patient dosed in October 2024 — but Recursion discontinued the program in its Q1 2025 update (May 2025), citing low recurrence rates with existing therapies and seeking out-licensing, so no preliminary efficacy readout was delivered by the end of 2025.